Humulin I (Isofano) (Insulin Human)

Humulin I (Isofano) is indicated for the management of diabetes mellitus in patients who need insulin supplementation. It may be used in various clinical scenarios where glycemic control is required.

• Treatment of type 1 diabetes mellitus when endogenous insulin production is insufficient.
• Adjunct therapy in type 2 diabetes mellitus when oral agents do not achieve target glucose levels.
• Management of gestational diabetes when diet and oral agents are inadequate.
• Perioperative glucose control in diabetic patients undergoing surgery.
• Emergency treatment of severe hyperglycemia or diabetic ketoacidosis under medical supervision.

• Insulin human binds to insulin receptors on the surface of muscle, adipose, and hepatic cells, activating the receptor's intrinsic tyrosine kinase activity. This triggers intracellular signaling pathways that promote translocation of glucose transporter proteins to the cell membrane, increasing glucose uptake. In the liver, insulin suppresses gluconeogenesis and glycogenolysis, thereby reducing hepatic glucose output and contributing to overall blood glucose regulation.

Humulin I (Isofano) may cause a range of adverse reactions, ranging from mild to severe. Awareness of these potential effects helps patients and clinicians monitor therapy.

Common

• Hypoglycemia (low blood glucose levels)
• Injection site reactions such as redness, swelling, or itching
• Lipodystrophy (localized changes in fat tissue)
• Weight gain
• Mild gastrointestinal discomfort

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures
• Allergic reactions including rash, urticaria, or anaphylaxis
• Edema (swelling) of the extremities
• Persistent hyperglycemia indicating inadequate dosing
• Rare cases of insulin antibody formation affecting glucose control

Before initiating Humulin I (Isofano), certain precautions should be considered to ensure safe use.

• Verify blood glucose levels regularly to avoid hypoglycemia.
• Adjust doses during periods of illness, stress, or changes in physical activity.
• Use caution in patients with renal or hepatic impairment, as insulin clearance may be altered.
• Monitor for signs of allergic reactions, especially after the first few injections.
• Pregnant or breastfeeding individuals should discuss risks and benefits with their healthcare provider.
• Store the product according to manufacturer instructions to maintain potency.

Humulin I (Isofano) can interact with several medications and substances, affecting its efficacy or safety.

Avoid

• Concurrent use of other rapid-acting insulins without proper dose adjustment.
• High-dose beta‑blockers, which may mask hypoglycemia symptoms.
• MAO inhibitors that can potentiate insulin's hypoglycemic effect.
• Alcohol excess, which can cause unpredictable blood glucose fluctuations.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk.
• Corticosteroids, which may raise blood glucose and require dose changes.
• Thyroid hormones, as hyperthyroidism can enhance insulin clearance.
• Diuretics, particularly thiazides, which may affect glucose tolerance.